Multiple Myeloma Articles | Page 3

Fonseca Discusses Integrating Biology and Treatment in Multiple Myeloma
Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.
Triplets Reign Supreme in Relapsed/Refractory Myeloma
Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.
 
Denosumab Approved in Europe for Myeloma
The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.
 
Ongoing Advances Transforming Treatment in Myeloma
Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.
Myeloma Expert Provides Insight on Practice-Changing Data
Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma. 
Berdeja Looks Ahead in Multiple Myeloma Treatment
Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.
Denosumab Approaches European Approval for Myeloma
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Pomalidomide Effective in Multiple Myeloma With Renal Impairment
Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.
Pivotal Denosumab Data Published Highlighting Efficacy in Myeloma
Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.
Expert Highlights Early Promise of Selinexor in Myeloma
Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.
Publication Bottom Border
Border Publication
x